Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
J Appl Microbiol ; 123(6): 1561-1570, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28948675

ABSTRACT

AIMS: To confirm the stress-relieving effects of heat-inactivated, enteric-colonizing Lactobacillus gasseri CP2305 (paraprobiotic CP2305) in medical students taking a cadaver dissection course. METHODS AND RESULTS: Healthy students (21 males and 11 females) took paraprobiotic CP2305 daily for 5 weeks during a cadaver dissection course. The General Health Questionnaire and the Pittsburgh Sleep Quality Index were employed to assess stress-related somatic symptoms and sleep quality respectively. The aggravation of stress-associated somatic symptoms was observed in female students (P = 0·029). Sleep quality was improved in the paraprobiotic CP2305 group (P = 0·038), particularly in men (P = 0·004). Among men, paraprobiotic CP2305 shortened sleep latency (P = 0·035) and increased sleep duration (P = 0·048). Diarrhoea-like symptoms were also effectively controlled with CP2305 (P = 0·005) in men. Thus, we observed sex-related differences in the effects of paraprobiotic CP2305. In addition, CP2305 affected the growth of faecal Bacteroides vulgatus and Dorea longicatena, which are involved in intestinal inflammation. CONCLUSIONS: CP2305 is a potential paraprobiotic that regulates stress responses, and its beneficial effects may depend on specific cell component(s). SIGNIFICANCE AND IMPACT OF THE STUDY: This study characterizes the effects of a stress-relieving para-psychobiotic in humans.


Subject(s)
Lactobacillus gasseri , Probiotics/therapeutic use , Sleep , Stress, Psychological/drug therapy , Adult , Feces/microbiology , Female , Humans , Male , Sex Factors , Students, Medical
2.
J Appl Microbiol ; 122(1): 212-224, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27761980

ABSTRACT

AIMS: To clarify the effects of Lactobacillus gasseri CP2305 (CP2305) on quality of life and clinical symptoms and its functional mechanisms in patients with irritable bowel syndrome (IBS). METHODS AND RESULTS: After the patients were administered CP2305 daily for 4 weeks, the IBS-severity index score was significantly improved compared with that of the placebo group, and this improvement was accompanied by a reduction in health-related worry and changes in intestinal microbiota. The gene expression profiling of the peripheral blood leucocytes showed that CP2305 treatment significantly up-regulated genes related to eukaryotic initiation factor 2 (EIF2) signalling. Eighty-two genes were down-regulated in IBS patients compared with healthy controls. The expression of 23 of these genes exhibited a CP2305-dependent increase associated with an improvement in IBS severity. The majority of the restored genes were related to EIF2 signalling. CONCLUSIONS: CP2305 administration is a potential candidate therapeutic option for patients with IBS. SIGNIFICANCE AND IMPACT OF THE STUDY: Although probiotics have been proposed to benefit IBS patients, objective clinical evidence and elucidation of the functional mechanism remain insufficient. Our study demonstrated that CP2305 administration beneficially influences IBS patients in both subjective and objective evaluations, and gene expression profiling provided insights into the functional mechanism.


Subject(s)
Irritable Bowel Syndrome/drug therapy , Lactobacillus gasseri/physiology , Probiotics/administration & dosage , Adult , Female , Humans , Irritable Bowel Syndrome/genetics , Irritable Bowel Syndrome/metabolism , Male , Middle Aged , Quality of Life , Treatment Outcome
3.
J Dairy Sci ; 88(2): 527-33, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15653517

ABSTRACT

Studies in animals have suggested that lactic acid bacteria alleviate allergic diseases, however, little information is available on their clinical effect on allergy in humans. Thus, we examined the efficacy of orally administered Lactobacillus acidophilus strain L-92 (L-92) on perennial allergic rhinitis. In a randomized, double-blind, placebo-controlled clinical trial, 49 patients with perennial allergic rhinitis were randomized to receive either 100 mL of heat-treated fermented milk containing L-92 (n = 25) or acidified milk without lactic acid bacteria (placebo; n = 24) for 8 wk. The severity of symptoms was evaluated based on the changes in the scores of clinical symptoms. Oral administration of milk fermented with L-92 resulted in a statistically significant improvement of nasal symptom-medication scores. Ocular symptom-medication scores of patients in the L-92 intervention group tended to improve compared with those in the placebo group. In addition, clear decreases of the scores of swelling and color of the nasal mucosa were observed in the L-92 intervention group at 6 and 8 wk after the start of ingestion of fermented milk. There were no significant differences in serum antihouse dust mite immunoglobulin E levels nor in T helper type 1/T helper type 2 ratio between the 2 groups. These results suggest that oral administration of L-92 can alleviate the symptoms of perennial allergic rhinitis, however, statistically significant changes were not shown in blood parameters.


Subject(s)
Lactobacillus acidophilus , Rhinitis, Allergic, Perennial/therapy , Animals , Double-Blind Method , Fermentation , Food Handling/methods , Hot Temperature , Humans , Immunoglobulin E/blood , Leukocyte Count , Milk , Mucus , Nasal Cavity/pathology , Nasal Mucosa/pathology , Placebos , Pyroglyphidae/immunology , Rhinitis, Allergic, Perennial/immunology , Rhinitis, Allergic, Perennial/pathology , Th1 Cells , Th2 Cells
4.
Angew Chem Int Ed Engl ; 39(1): 209-213, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10649378

ABSTRACT

A catalytic version has now been developed for the enantioselective total synthesis of epothilone A (1). The key is the use of multifunctional asymmetric catalyses for a direct aldol reaction and cyanosilylation. This successful approach demonstrated the usefulness of these reactions for the catalytic asymmetric synthesis of complex molecules.

5.
Chem Pharm Bull (Tokyo) ; 44(2): 463-5, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8998847

ABSTRACT

13-Deacetoxy-11-demethyl-phorbol derivatives with acyl groups of various lengths (from hexanoyl to tetradecanoyl) at the C-12 position were synthesized in an optically active form. Although considerable binding affinities to PKC were observed by analogs 3-7, no activation of PKC was seen even at 10 microM.


Subject(s)
Phorbol Esters/metabolism , Protein Kinase C/metabolism , Binding, Competitive/drug effects , Enzyme Activation/drug effects , Phorbol 12,13-Dibutyrate/metabolism , Phorbol Esters/chemical synthesis , Protein Binding
6.
Naika ; 27(2): 334-8, 1971 Feb.
Article in Japanese | MEDLINE | ID: mdl-5100555

Subject(s)
Aged , Autopsy , Humans
9.
Naika ; 17(6): 1167-74, 1966 Jun.
Article in Japanese | MEDLINE | ID: mdl-5964797
SELECTION OF CITATIONS
SEARCH DETAIL
...